EntreMed, Inc. (ENMD) news stock charts
EntreMed, Inc. (ENMD) Investment Summary:
EntreMed, Inc. (“EntreMed” or “the Company”) (Nasdaq: ENMD) is a clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells and the blood vessels that nourish them. We are focused on developing drugs that we believe are safe and convenient, and provide the potential for improved patient outcomes. Our goal is to develop and commercialize therapeutics based on our scientific expertise in angiogenesis, cell cycle regulation and inflammation — processes vital to the progression of cancer and other diseases. This expertise has also led to the identification of new molecules, including new chemical entities derived from 2ME2 (2-methoxyestradiol), as well as new chemical entities associated with multi-kinase inhibition and histone deactylase (HDAC) inhibition, important targets in the treatment of oncology. We currently have four product candidates in clinical development that are based on these mechanisms. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f06%2f0000950133-08-000975.html#FIS_BUSINESS"www.entremed.com
21 Employees
Founded in 1991
ENTREMED INC (ENMD:NASDAQ)
LAST $0.72 USD
CHANGE TODAY -0.0126 -1.72%
VOLUME 73.7K
As of 10:49 AM 03/19/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of ENTREMED INC (ENMD)
|
OPEN
$0.76
|
PREVIOUS CLOSE
$0.73
|
|
|
DAY HIGH
$0.76
|
DAY LOW
$0.72
|
|
|
52 WEEK HIGH
11/12/09 - $1.53
|
52 WEEK LOW
03/20/09 - $0.17
|
|
|
MARKET CAP
64.0M
|
AVERAGE VOLUME 10 D
152.9K
|
|
|
EPS TTM
$-0.10
|
SHARES OUTSTANDING
88.7M
|
|
|
ENMD Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for ENTREMED INC (ENMD)
EntreMed Inc. Receives Orphan Drug Designation from FDA for ENMD-2076 in Leukemia
02/16/2010
EntreMed Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company's oncology drug candidate, ENMD-2076, for the treatment of acute myeloid leukemia (AML). The FDA accepted EntreMed's application upon review of preclinical data as well as initial data from its ongoing Phase 1 clinical study with ENMD-2076 in patients with relapsed or refractory acute myeloid leukemia (AML). As previously presented, initial results from the Phase 1 study demonstrated that ENMD-2076, administered orally as a single agent, was well tolerated in this patient population. The data for 15 evaluable AML patients showed that one patient achieved a CRi (complete remission with incomplete hematological recovery) and two patients achieved a morphologic leukemia-free state (MLFS). Three additional patients participating in the study experienced 11%, 14% and 65% reductions in marrow blast count. Orphan drug is a designation by the U.S. Food and Drug Administration indicating a therapy developed to treat diseases that affect fewer than 200,000 persons in the United States.
EntreMed Receives Letter From NASDAQ
01/20/2010
On January 19, 2010, EntreMed Inc. received a NASDAQ Staff Determination letter indicating that the Company failed to comply with NASDAQ Listing Rule 5450(a)(1) for continued listing on The NASDAQ Capital Market. Rule 5450(a)(1) requires that a listed company maintain a minimum closing bid price of at least $1 per share. The Company had initially been notified by NASDAQ of such minimum bid price deficiency on April 4, 2008, as previously announced on a Current Report on Form 8-K. As a result of suspensions by NASDAQ of enforcement of the bid price due to extraordinary market conditions, the Company had until January 15, 2010 to regain compliance. As the Company has not regained compliance with such NASDAQ rule, the NASDAQ Staff has determined to delist its securities from the NASDAQ Capital Market on January 28, 2010, unless the Company requests an appeal of the determination. On January 20, 2010, the Company filed an appeal of the Staff's determination to a NASDAQ Hearings Panel (the Panel), pursuant to the procedures set forth in the NASDAQ Marketplace Rules. The hearing request will stay the delisting of the Companys securities pending the Panel's decision. The Company expects to provide the Panel with a plan of action, with the intention of returning to compliance with NASDAQs requirements.
Entremed Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2009
12/14/2009
EntreMed Inc. expects a drop in fourth quarter and projected revenue for fiscal 2009.
EntreMed, Inc. financial resources
ENMD Competitors
| Company | Last | Change |
| Celgene Corp | $64.97 USD | -0.05 |
| Eisai Co Ltd | ¥3,640 JPY | +40.00 |
| Gentium SpA | $2.61 USD | +0.98 |
| Genzyme Corp | $59.02 USD | +1.61 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | ENMD | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 8.4x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 5.7x |
|
|
ENMD |
||
|
ENMD transactions
| Type Date |
Target |
|
Private Placement
February 3, 2010 |
-- |
|
Private Placement
January 8, 2010 |
-- |
More Recent Financial News About EntreMed, Inc.
EntreMed Raises Additional $2.5 Million In Registered Direct Offering
2010-03-01 05:08:42
Quote: 4 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) today announced that it completed a registered direct offering of 3,846,154 shares of its common stock, at a purchase price of $0.65 per share, to a single accredited institutional investor. Â The sale resulted in gross proceeds to the Company of $2.5 million. Â The terms of the purchase were set forth in a stock purchase agreement entered into by the parties on February 3, 2010. The per share purchase price reflects a 10% discount to...Read article
EntreMed Raises Additional $2.5 Million In Registered Direct Offering
2010-02-05 12:01:13
Quote: 4 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) today announced that it completed a registered direct offering of 3,846,154 shares of its common stock, at a purchase price of $0.65 per share, to a single accredited institutional investor. Â The sale resulted in gross proceeds to the Company of $2.5 million. Â The terms of the purchase were set forth in a stock purchase agreement entered into by the parties on February 3, 2010. The per share purchase price reflects a 10% discount to...Read article
ENTREMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
2010-02-05 12:01:12
Quote: Entry Into a Material Definitive Agreement.
On February 3, 2010, EntreMed, Inc., a Delaware corporation ("EntreMed"),
consummated the issuance and sale (the "Offering") of 3,846,154 shares of its
common stock, par value $0.01 per share (the "Shares") to an institutional
investor (the "Investor"). The Offering was made pursuant to a stock purchase
agreement dated as of February 3, 2010 (the "Stock Purchase Agreement") between
EntreMed and the Inv...Read article
EntreMed Receives NASDAQ Staff Determination Letter Regarding Noncompliance with Minimum Bid Price Rule and Requests Hearing
2010-01-29 05:29:46
Quote: 20 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) today announced that on January 19, 2010, it received a Staff Determination letter from the NASDAQ Stock Market (NASDAQ) stating that the Company has not regained compliance with the $1.00 minimum closing bid price requirement for continued listing under the NASDAQ Listing Rule 5450(a)(1), and that its common stock is, therefore, subject to delisting from the NASDAQ Capital Market. Â The letter states that, unless EntreMed requests a h...Read article
EntreMed Receives NASDAQ Staff Determination Letter Regarding Noncompliance with Minimum Bid Price Rule and Requests Hearing
2010-01-21 05:18:12
Quote: 20 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) today announced that on January 19, 2010, it received a Staff Determination letter from the NASDAQ Stock Market (NASDAQ) stating that the Company has not regained compliance with the $1.00 minimum closing bid price requirement for continued listing under the NASDAQ Listing Rule 5450(a)(1), and that its common stock is, therefore, subject to delisting from the NASDAQ Capital Market. Â The letter states that, unless EntreMed requests a h...Read article
ENTREMED INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Tran
2010-01-21 05:18:11
Quote: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing
On January 19, 2010, EntreMed, Inc. (the "Company") received a NASDAQ Staff
Determination letter indicating that the Company failed to comply with NASDAQ
Listing Rule 5450(a)(1) for continued listing on The NASDAQ Capital Market.
Rule 5450(a)(1) requires that a listed company maintain a minimum closing bid
price of at least $1.00 per share.
The Company had initially been notified by N...Read article
EntreMed Completes Registered Direct Offering of $2.5 Million in Common Stock
2010-01-19 03:33:50
Quote: 12 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) today announced that, on January 11, 2010, it completed a registered direct offering of 3,125,000 shares of its common stock, at a purchase price of $0.80 per share, to a single accredited institutional investor. Â The sale resulted in gross proceeds to the Company of $2.5 million. Â The terms of the purchase were set forth in a stock purchase agreement entered into by the parties on January 8, 2010. Â The per share purchase price ...Read article
EntreMed Reports Receipt of Third Quarter Royalty Payment
2010-01-19 03:33:50
Quote: 11 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), today announced the receipt of $1.7 million in royalty revenue from sales of Thalomid® during the third quarter compared to estimated royalty revenue of $3.3 million.  In addition, the Company anticipates a decrease in fourth quarter and projected revenue for fiscal 2009.  The difference in estimated and actual revenues for the third quarter will be reflected in the fourth quarter financial results.http://www.newscom.com/cgi-bi...Read article
EntreMed Completes Registered Direct Offering of $2.5 Million in Common Stock
2010-01-13 01:51:16
Quote: 12 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) today announced that, on January 11, 2010, it completed a registered direct offering of 3,125,000 shares of its common stock, at a purchase price of $0.80 per share, to a single accredited institutional investor. Â The sale resulted in gross proceeds to the Company of $2.5 million. Â The terms of the purchase were set forth in a stock purchase agreement entered into by the parties on January 8, 2010. Â The per share purchase price ...Read article
ENTREMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
2010-01-13 01:51:15
Quote: Entry Into a Material Definitive Agreement.
On January 11, 2010, EntreMed, Inc., a Delaware corporation ("EntreMed"),
consummated the issuance and sale (the "Offering") of 3,125,000 shares of its
common stock, par value $0.01 per share (the "Shares") to an institutional
investor (the "Investor"). The Offering was made pursuant to a stock purchase
agreement dated as of January 8, 2010 (the "Stock Purchase Agreement") between
EntreMed and the Inve...Read article
EntreMed Reports Receipt of Third Quarter Royalty Payment
2009-12-14 01:18:01
Quote: 11 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), today announced the receipt of $1.7 million in royalty revenue from sales of Thalomid® during the third quarter compared to estimated royalty revenue of $3.3 million.  In addition, the Company anticipates a decrease in fourth quarter and projected revenue for fiscal 2009.  The difference in estimated and actual revenues for the third quarter will be reflected in the fourth quarter financial results.http://www.newscom.com/cgi-bi...Read article
ENTREMED INC Files SEC form 8-K, Results of Operations and Financial Condition
2009-11-30 06:43:16
Quote: Item 2.02 Results of Operations and Financial Condition.
On August 6, 2009 EntreMed, Inc. (the "Company") issued a press release
reporting its financial results for the three and six-month periods ending
June 30, 2009. The press release is furnished as Exhibit 99.1 to this Current
Report on Form 8-K.
The information on this Current Report on Form 8-K (including Exhibit 99.1)
shall not be deemed "filed" for purposes of Section 18 of the Securities Act of
1934, as amended (t...Read article
Data for EntreMed's ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC Conference
2009-11-30 06:43:15
Quote: Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid®, risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicati...Read article
ENTREMED INC Files SEC form 8-K, Results of Operations and Financial Condition
2009-11-30 06:43:13
Quote: Item 2.02 Results of Operations and Financial Condition.
On November 16, 2009 EntreMed, Inc. (the "Company") issued a press release
reporting its financial results for the three and nine-month periods ending
September 30, 2009. The press release is furnished as Exhibit 99.1 to this
Current Report on Form 8-K.
The information on this Current Report on Form 8-K (including Exhibit 99.1)
shall not be deemed "filed" for purposes of Section 18 of the Securities Act of
1934, as a...Read article
EntreMed Reports Third Quarter 2009 Financial Results
2009-11-30 06:43:13
Quote: Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid®, risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicati...Read article
Would you like to leave a comment about EntreMed, Inc. ENMD
Find out what social network information about EntreMed, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides EntreMed, Inc.'s Stock there is more great penny stock and market information at Realpennies